TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Dec 11, 2020 10:43 JST
Source:
Eisai
Eisai: Biogen Files New Drug Application for Aducanumab in Japan
- If approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimer's disease
- Aducanumab is now under regulatory review in Japan, Europe and the United States
TOKYO, Dec 11, 2020 - (JCN Newswire) - Biogen and Eisai, Co., Ltd. (Tokyo, Japan) announced that Biogen has submitted a Japanese New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) for aducanumab, an investigational therapy for Alzheimer's disease. Aducanumab, an amyloid beta-targeting antibody, has been shown in clinical trials to remove amyloid beta in the brain and significantly slow clinical decline in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and mild Alzheimer's disease dementia.
"Japan is the third market where we have applied for regulatory approval for aducanumab, and the filing represents continued progress on our commitment to bring this therapy to patients around the world," said Michel Vounatsos, Chief Executive Officer at Biogen. "Japan has met the challenges of a rapidly-aging population by demonstrating global leadership in setting policies that aim to increase support for Alzheimer's disease patients and caregivers. We look forward to the regulatory review of aducanumab with the hope that, if approved, it could help further manage the impact of this devastating disease."
"As Japan has the oldest population in the world, it is anticipated that the social burden of Alzheimer's disease will continue to grow," said Dr. Haruo Naito, Chief Executive Officer at Eisai Co., Ltd. "For more than 30 years, Eisai has been dedicated to dementia research and development, and working with people living with Alzheimer's and their caregivers to fight this disease. The filing of the application is an important step in serving patients and their families as aducanumab may help reduce clinical decline and potentially maintain the ability to live an independent life for as long as possible. Aducanumab also has the potential to help address the public health challenges our aging population faces in Japan."
The Japanese regulatory authority will review the application through the standard review process. In addition to the filing in Japan, aducanumab is under Priority Review with the U.S. Food and Drug Administration, with a Prescription Drug User Fee Act (PDUFA) action date of March 7, 2021 and is also under review with the European Medicines Agency.
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 10 2026 12:34 JST
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 06 2026 10:31 JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
More Press release >>
Latest Press Release
International Women's Day: Why Menopause May Be a Missed Cardiovascular Risk Window
Mar 06, 2026 20:00 JST
TANAKA Develops World's First High-Performance Palladium Hydrogen Permeable Membrane Exhibiting High Hydrogen Purification Performance at Temperatures around 100 degrees C
Mar 05, 2026 22:00 JST
Honda to Begin Sales of Two U.S.-built Vehicles in Japan
Mar 05, 2026 16:47 JST
DOCOMO's New Haptic-sharing System Enables Fans to Feel Closer to Idols
Mar 05, 2026 16:38 JST
TANAKA Establishes Transfer Technology for its Sintered Gold (Au) Bonding Technology, AuRoFUSE(TM) Preforms
Mar 03, 2026 22:00 JST
Fujitsu and BCN Port Innovation Foundation leverage ocean digital twin technology to drive the regeneration of the Port of Barcelona
Mar 03, 2026 21:00 JST
MHI and SoftBank Corp. Collaborate to Adapt AI-RAN Network Architecture for Edge Data Centers
Mar 02, 2026 19:13 JST
DOCOMO and NEC Launch Japan's First Commercial 5G Core on AWS, Built with World's First AI-automated Network Construction Technology
Mar 02, 2026 16:34 JST
Fujitsu supports sustainable growth for retailers with data and AI through Uvance for Retail
Mar 02, 2026 11:55 JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Mar 02, 2026 09:49 JST
NEC Strengthens Multi-Vendor Optical Network Solutions with New TIP-Certified Phoenix Hardware Lineup
Feb 27, 2026 18:50 JST
NEC Demonstrates Agentic AI-Driven Autonomous Network Operations in Collaboration with AWS
Feb 27, 2026 17:31 JST
Mitsubishi Heavy Industries Compressor Acquires Swiss Rotating Equipment Maintenance Company AST Turbo AG
Feb 27, 2026 17:23 JST
NEC Strengthens Its Edge Portfolio for the 6G Era, Enabling Efficient Edge Deployment and Integration with Cloud Services
Feb 27, 2026 12:24 JST
Fujitsu POS solution enhances customer experience at Hankyu Hanshin Department Stores
Feb 27, 2026 12:03 JST
Mitomo Semicon Engineering to Change Company Name
Feb 26, 2026 22:00 JST
The University of Tokyo, NTT, and NEC demonstrate real-time augmented reality assistance made possible by integrating three newly proposed technologies on a 6G/IOWN platform to realize the widespread use of AI agents supporting safety and security
Feb 26, 2026 19:01 JST
NEC and Nokia to Expand Eletronet's Optical Fiber Network in Brazil by 50%
Feb 26, 2026 18:51 JST
Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM
Feb 25, 2026 21:59 JST
Toyota Launches New bZ4X Touring BEV Focused on Driving Performance and Spaciousness in Japan
Feb 25, 2026 21:58 JST
More Latest Release >>